Medifast Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $316.9M-47.4% YoYTTM through 30 Jun 2026
Net Income -$25.6M-1,324.4% YoYTTM through 30 Jun 2026
Free Cash Flow $4MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 68.1% |
| EBITDA Margin | -1.8% |
| Operating Margin | -4.3% |
| Net Margin | -8.1% |
Returns
-1.1%ROE
-0.8%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio4.80x
Net Debt-$168.9Mnet cash position
Cash & Equivalents$71.9M
Quality Metrics
Altman Z-Score3.80
Piotroski F-Score3 / 9
FCF Margin1.3%
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $385.8M
Diluted EPS-$2.32TTMFY2025: $-1.70
Dividend
$4.95Per share, FY20230.00%Yield+17.7%5-yr growth
Capital Allocation
R&D Spend$4.3M
Capex Intensity1.5%
Segment Performance
Figures as of 31 Mar 2026
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| OPTAVIA Coach Network | View detailsManagement expects continued pressure on client acquisition and coach counts through 2026 due to rapid adoption of GLP-1 weight loss medications. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.